Abstract
In the last few years there is progress in treatment for patients with hepatocellular carcinoma. Nowadays, we do have three treatment options for first line setting (sorafenib, lenvatinib and atezolizumab + bevacizumab) and three treatment options for second line setting (regorafenib, cabozantinib and ramucirumab).
Immunotherapy has important role for hepatocellular carcinoma patients. This review aims to summarize current treatment options focusing on advanced stages of disease.